Menu
Logo

Looking to the Future

We would like to share with you the below information regarding role of Erleada (apalutamide 60 mg) in prolongation of second PFS*in patients with Metastatic hormone-sensitive prostate cancer.1

LOOK TO THE FUTURE FOR YOUR PATIENTS WITH mHSPC*2
Treating early with ERLEADA®+ADT*** provides second PFS* benefits vs Placebo+ADT2

[api:media-embed[725641,"file_field_image",{"settings":{"image_style":"","image_link":""}}]/]

Abbreviations:
*P-value was not reported.
*PFS=progression Free Survival
**mHSPC=metastatic hormone-sensitive prostate cancer
***ADT=androgen deprivation therapy
HR: hazard ratio, CI: Confidence interval
Second progression-free survival was the time from date of randomization to first occurrence of investigator-determined disease progression (PSA progression, progression on imaging, or clinical progression) while patient was receiving first subsequent therapy for prostate cancer or death due to any cause, whichever occurs first.

Study Details:3
Objective:
In this double-blind, phase 3 trial, we randomly assigned patients with metastatic, castration sensitive prostate cancer to receive apalutamide (240 mg per day) or placebo, added to ADT.
The primary end points were radiographic progression–free survival and overall survival.

Study Design:
A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The median age was 68 years. A total of 16.4% of the patients had undergone prostatectomy or received radiotherapy for localized disease, and 10.7% had received previous docetaxel therapy; 62.7% had high-volume disease, and 37.3% had low-volume disease. At the first interim analysis, with a median of 22.7 months of follow up, the percentage of patients with radiographic progression–free survival at 24 months
was 68.2% in the apalutamide group and 47.5% in the placebo group (hazard ratio for radiographic progression or death, 0.48; 95% confidence interval [CI], 0.39 to 0.60; P<0.001). Overall survival at 24 months was also greater with apalutamide than with placebo
(82.4% in the apalutamide group vs. 73.5% in the placebo group; hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005). The frequency of grade 3 or 4 adverse events was 42.2% in the apalutamide group and 40.8% in the placebo group; rash was more common in the apalutamide group.

References:
1. SmPC of Erleada®.EMA. Last revised 27/1/2020. Last accessed 8/12/2020. https://www.medicines.org.uk/emc/product/9832/smpc/print.
2.Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019; 381 (1) : 13-24.Supplementary information.
3. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019; 381 (1): 13-24.

ERLEADA® IMPORTANT SAFETY INFORMATION
Therapeutic indications
Erleada is indicated

  • in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
  • in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

Dose
The recommended dose is 240 mg (four 60 mg tablets) as an oral single daily dose.


Contraindications
Hypersensitivity to the active substance or to any of the excipients.
Women who are or may become pregnant.


Special warnings and precautions for use Seizure:
Erleada is not recommended in patients with a history of seizures or other predisposing factors including, but not limited to, underlying brain injury, recent stroke (within one year), primary brain tumors or brain metastases. If a seizure develops during treatment with Erleada, treatment should be discontinued permanently. The risk of seizure may be increased in patients receiving concomitant medicinal products that lower the seizure threshold. Seizure occurred in 0.2% of patients receiving
Erleada in clinical studies. These studies excluded patients with a history of seizure or predisposing factors for seizure.
There is no clinical experience in re-administering Erleada to patients who experienced a seizure.


Falls and fractures:

Falls and fractures occurred in patients receiving Erleada. Patients should be evaluated for fractures and fall risk before starting Erleada and should continue to be monitored and managed for fractures according to established treatment guidelines and use of bone-targeted agents should be considered

Concomitant use with other medicinal products:
Apalutamide is a potent enzyme inducer and may lead to loss of efficacy of many commonly used medicinal products. A review of concomitant medicinal products should therefore be conducted when apalutamide treatment is initiated. Concomitant use of apalutamide with medicinal products that are sensitive substrates of many metabolising enzymes or transporters should generally be avoided if their therapeutic effect is of large importance to the patient, and if dose adjustments
cannot easily be performed based on monitoring of efficacy or plasma concentrations.
Co-administration with warfarin and coumarin-like anticoagulants should be avoided. If Erleada is co-administered with an anticoagulant metabolised by CYP2C9 (such as warfarin or acenocoumarol), additional International Normalized Ratio (INR) monitoring should be conducted.


Recent cardiovascular disease:
Patients with clinically significant cardiovascular disease in the past 6 months including severe/ unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous
thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias were excluded from the clinical studies. Therefore, the safety of apalutamide in these patients has not been established.

If Erleada is prescribed, patients with clinically significant cardiovascular disease should be monitored for risk factors such as hypercholesterolaemia, hypertriglyceridaemia, or other cardiometabolic disorders.
Patients should be treated, if appropriate, after initiating Erleada for these conditions according to established treatment guidelines.


Androgen deprivation therapy may prolong the QT interval
In patients with a history of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval physicians should assess the benefit-risk ratio including the potential for Torsade de pointes prior to initiating Erleada.


Fertility, pregnancy and lactation:
Contraception in males and females
It is not known whether apalutamide or its metabolites are present in semen. Erleada may be harmful to a developing fetus. For patients having sex with female partners of reproductive potential, a condom should be used along with another highly effective contraceptive method during treatment and for 3 months after the last dose of Erleada.


Pregnancy
action, Erleada may cause fetal harm when administered during pregnancy. There are no data available from the use of Erleada in pregnant women. Animal reproductive studies have not been conducted with Erleada.


Breast-feeding
It is unknown whether apalutamide/metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. Erleada should not be used during breast-feeding.


Fertility
Effects on ability to drive and use machines
Erleada has no or negligible influence on the ability to drive and use machines. However, seizures have been reported in patients taking Erleada. Patients should be advised of this risk in regards to driving or operating machines.


Undesirable effects
Summary of the safety profile

The most common adverse reactions are fatigue (30%), skin rash (24% of any grade and 5% Grade 3 or 4), weight decreased (16%), arthralgia (16%), and fall (16%). Other important adverse reactions include fractures (12%) and hypothyroidism (8%).
Tabulated list of adverse reactions Adverse reactions observed during clinical studies are listed below by frequency category.
Frequency categories are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (frequency cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Table 1: Adverse reactions identified in clinical studies

System organ class
Adverse reaction and frequency
Endocrine disorders
common: hypothyroidism*
Metabolism and nutrition disorders

common: hypercholesterolaemia
common: hypertriglyceridaemia

very common: decreased appetite

Nervous system disorders
uncommon: seizure
Cardiac disorders
not known: QT prolongation
Skin and subcutaneous tissue disorders
very common: skin rash**
common: pruritus
Musculoskeletal and connective tissue
disorders
very common: fracture+
very common: arthralgia
General disorders and administration site conditions
very common: fatigue
Investigations
very common: weight decreased
Injury, poisoning and procedural
complications
very common: fall

* Includes hypothyroidism, blood thyroid stimulating hormone increased, thyroxine decreased, autoimmune thyroiditis, thyroxine free decreased, tri-iodothyronine decreased
** See “Skin rash” under “Description of selected adverse reactions”
+ Includes rib fracture, lumbar vertebral fracture, spinal compression fracture, spinal fracture, foot fracture, hip fracture, humerus fracture, thoracic vertebral fracture, upper limb fracture, fractured sacrum, hand fracture, pubis fracture, acetabulum fracture, ankle fracture, compression fracture, costal cartilage fracture, facial bones fracture, lower limb fracture, osteoporotic fracture, wrist fracture, avulsion fracture, fibula fracture, fractured coccyx, pelvic fracture, =radius fracture, sternal fracture, stress fracture, traumatic fracture, cervical vertebral fracture, femoral neck fracture, tibia fracture. See below.

Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
- Always read the full prescribing information.
- Healthcare professionals are asked to report any suspected adverse reactions to Egyptian pharmacovigilance center (EPVC).
- MOH leaflet approval date: 11/2020.


image
image

CP-214611